DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapyECCO’23 CopenhagenYear: 2023
Authors: Lee, H.S.(1)*;Lee, Y.(1);Baek, J.(1);Kim, Y.(1);Park, S.(1);Jung, S.(1);Kim, K.K.(2);Hwang, S.W.(2);Lee, J.L.(3);Park, S.H.(2);Yang, S.K.(2);Han, B.(4);Song, K.(1);Yoon, Y.S.(3);Ye, B.D.(2);
(1)University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center, Department of Surgery, Seoul, Korea- Republic Of;(4)Seoul National University College of Medicine, Department of Biomedical Sciences, Seoul, Korea- Republic Of;
DOP82: Biological Treatment Cycles in Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Noor, N.(1)*;Sousa, P.(2);Bettenworth, D.(3);Gomollon, F.(4);Lobaton, T.(5,6);Bossuyt, P.(7);Casanova, M.J.(8);Ding, N.(9);Dragoni, G.(10,11);Furfaro, F.(12);van Rheenen, P.(13);Chaparro, M.(8);Gisbert, J.(8);Louis, E.(14);Papamichael, K.(15);
(1)Addenbrooke's Hospital- Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(2)Viseu Unit- Tondela-Viseu Hospital Centre, Department of Gastroenterology, Viseu, Portugal;(3)University of Münster, Medical Faculty of the University of Münster, Münster, Germany;(4)Hospital Clínico Universitario Lozano Blesa, Department of Gastroenterology, Zaragoza, Spain;(5)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(6)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(7)Imelda GI Clinical Research Centre, Department of Gastroenterology, Bonheiden, Belgium;(8)Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit- Hospital Universitario de La Princesa, Madrid, Spain;(9)University of Melbourne- St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(10)University of Florence, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio'- Gastroenterology Research Unit, Florence, Italy;(11)Careggi University Hospital, IBD Referral Center- Gastroenterology Department, Florence, Italy;(12)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(13)University Medical Center Groningen, Department of Paediatric Gastroenterology, Groningen, The Netherlands;(14)Liege University Hospital- CHU Liege, Department of Hepato-Gastroenterology and Digestive Oncology, Liege, Belgium;(15)Beth-Israel Deaconess Medical Center- Harvard Medical School, Center for Inflammatory Bowel Diseases- Division of Gastroenterology, Boston, United States;
DOP83: Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn's disease receiving maintenance infliximab: A randomized controlled trialECCO’23 CopenhagenYear: 2023
Authors: Kang, B.(1)*;Moon, J.S.(2);Lee, Y.J.(3);Kim, M.J.(4);Choe, B.H.(1);Ko, J.S.(2);Park, J.H.(3);Choe, Y.H.(4);
(1)Kyungpook National University School of Medicine, Department of Pediatrics, Daegu, Korea- Republic Of;(2)Seoul National University College of Medicine, Department of Pediatrics, Seoul, Korea- Republic Of;(3)Pusan National University College of Medicine, Department of Pediatrics, Yangsan, Korea- Republic Of;(4)Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, Korea- Republic Of;
DOP84: IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational studyECCO’23 CopenhagenYear: 2023
Authors: Sebastian, S.(1)*;Siegel, C.(2);Siegmund, B.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
(1)Hull University Teaching Hospital, IBD Unit, Hull, United Kingdom;(2)Dartmouth Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, United States;(3)Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;(4)Takeda, Gastroenterology, Cambridge- MA, United States;(5)Takeda, Gastroenterology, Zurich, Switzerland;(6)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;
DOP85: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.ECCO’23 CopenhagenYear: 2023
Authors: Schulberg, J.(1,2)*;Hamilton, A.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Lovett, G.(1,2);Sutherland, T.(2,3);Ross, A.(1);Vogrin, S.(2);Kamm, M.(1,2);
(1)St. Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St. Vincent's Hospital Melbourne, Department of Radiology, Melbourne, Australia;
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).ECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Hanauer, S.B.(2);Sandborn, W.(3);Sands, B.E.(4);Schreiber, S.(5);Danese, S.(6);Kierkus, J.(7);Kulynych, R.(8);Klopocka, M.(9);Lahat, A.(10);Gonciarz, M.(11);Osipenko, M.(12);Borzan, V.(13);Kowalski, M.(14);Saenko, D.(15);Sardinov, R.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Yang, S.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Park, G.(18);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Northwestern University/ Feinberg School of Medicine, Gastroenterology and Hepatology, Chicago- IL, United States;(3)University of California San Diego, Gastroenterology, La Jolla, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)University Hospital Schleswig Holstein, Medicine I, Kiel, Germany;(6)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(7)The Children Memorial Health Institute, Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(8)Zaporizhzhia regional clinical hospital, Gastroenterology and Endoscopy, Zaporizhzhia, Ukraine;(9)Nicolaus Copernicus University- Collegium Medicum in Bydgoszcz, Gastroenterology and Nutrition Disorders, Bydgoszcz, Poland;(10)Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;(11)Military Institute of Medicine - National Research Institute, Gastroenterology and Internal Diseases, Warsaw, Poland;(12)Novosibirsk Medical University, Novosibirsk Medical University, Novosibirsk, Russian Federation;(13)Clinical Hospital Center Osijek- Faculty of medicine Osijek, Gastroenterology, Osijek, Croatia;(14)Centrum Diagnostyczno – Lecznicze Barska, Gastroenterology, Wloclawek, Poland;(15)LLC "Clinica UZI 4D", LLC "Clinica UZI 4D", Pyatigorsk- Stavropol Region, Russian Federation;(16)BioTechService LLC- St. Petersburg Medical and Social Institute, Therapy, Saint-Petersburg, Russian Federation;(17)Celltrion- Inc., Medical Science Division, Incheon, Korea- Republic Of;(18)Celltrion- Inc., Data Science Institute, Incheon, Korea- Republic Of;CT-P13 SC 3.8
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study ResultsECCO’23 CopenhagenYear: 2023
Authors: Feagan , B.G.(1)*;Sands , B.(2);Siegel , C.A.(3);Dubinsky , M.(4);Longman , R.(5);Sabinho , J.(6);Laurent , O.(7);Luo , A.(7);Lu, JD.(7);Nguyen, D.(7);Towfic , F.(7);DuVall, A.(8);Woyranowski , M.(9);Al Kharrat , H.(10);McGovern, D.P.B.(11);
(1)Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada;(2)Icahn School of Medicine at Mount Sinai, New York, New York, USA;(3)Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire,USA;(4)Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA;(5)Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA;(6)Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium;(7)Prometheus Biosciences, Inc., San Diego, CA, USA;(8)Tyler Research Institute, LLC, Tyler, TX,USA;(9)Department of Pediatrics, Faculty of Medicine and Health Sciences, UJK Kielce, former IP CZD Warsaw, Poland;(10)West Texas Digestive Disease Center, Lubbock, Texas,USA;(11)Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA;
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Lin, S.(1,2)*;Hannon, E.(3);Waring, J.F.(4);Reppell, M.(4);Smaoui, N.(4);Pivorunas, V.L.(4);Guay, H.(4);Chanchlani, N.(1,2);Bewshea, C.(2);Bai, B.Y.H.(5,6);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Mill, J.(3);Ahmad, T.(1,2);
(1)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)University of Exeter, University of Exeter Medical School- College of Medicine and Health, Exeter, United Kingdom;(4)AbbVie Inc, Research and Development, Chicago, United States;(5)Wellcome Sanger Institute, Genomics of Inflammation and Immunity Group, Hinxton, United Kingdom;(6)University of Cambridge, Postgraduate School of Life Sciences, Cambridge, United Kingdom;
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide studyECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Nancey, S.(2);Nachury, M.(3);Allez, M.(4);Rouillon, C.(5);Boureille, A.(6);Altwegg, R.(7);Serrero, M.(8);Vuitton, L.(9);Bouguen, G.(10);Abitbol, V.(11);Boualit, M.(12);Biron, A.(13);Panis, Y.(14);Laharie, D.(15);Amiot, A.(16);Simon, M.(17);Caillo, L.(18);Hébuterne, X.(19);Vidon, M.(20);Benezech, A.(21);Elgharabawy , Y.(22);Peyrin-biroulet, L.(23);
(1)Amiens University Hospital, Gastroenterology, Amiens, France;(2)Lyon University Hospital, Gastroenterology, Lyon, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Saint Louis Hospital, Gastroenterology, Paris, France;(5)Caen University Hospital, Gastroenterology, Caen, France;(6)Nantes University Hospital, Gastroenterology, Nantes, France;(7)Montpellier University Hospital, Gastroenterology, Montpellier, France;(8)Marseille University Hospital, Gastroenterology, Marseille, France;(9)Besancon University Hospital, Gastroenterology, Besancon, France;(10)Rennes University Hospital, Gastroenterology, Rennes, France;(11)Cochin Hospital, Gastroenterology, Paris, France;(12)Valenciennes Hospital, Gastroenterology, Valenciennes, France;(13)Reims University Hospital, Gastroenterology, Reims, France;(14)GH Privé Ambroise Paré-Hartmann, Colorectal surgery, Neuilly sur Seine, France;(15)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(16)Kremlin-Bicêtre Hospital, Gastroenterology, Kremlin-Bicêtre, France;(17)Institut Mutualiste Montsouris, Gastroenterology, Paris, France;(18)Nimes University Hospital, Gastroenterology, Nimes, France;(19)Nice University Hospital, Gastroenterology, Nice, France;(20)CHI Creteil, Gastroenterology, Creteil, France;(21)CH Avignon, Gastroenterology, Avignon, France;(22)GETAID, Getaid, Paris, France;(23)Nancy University Hospital, Gastroenterology, Nancy, France;GETAID
DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumabECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Sapin, C.(2);Chan-Diehl, F.W.(3);Moses, R.E.(3);Siegmund, B.(4);Walsh, A.(5);Kobayashi, T.(6);Parambir, D.S.(7);Travis, S.(8);
(1)University of Calgary, Faculty of Medicine at the Cumming School of Medicine, Calgary, Canada;(2)Eli Lilly France, Rheumatology & Gastroenterology – Real World & Access Analytics RWA² Global Statistical Sciences & Advanced Analytics, Neuilly sur Seine, France;(3)Eli Lilly and Company, Gastroenterology, Indianapolis, United States;(4)Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie- Infektiologie- Rheumatologie Charité, Berlin, Germany;(5)Nuffield Health- The Manor Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom;(6)Kitasato University -Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(7)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(8)Oxford University, Nuffield Department of Medicine, Oxford, United Kingdom;
N01: Using Item Response Theory to improve the efficiency of the Crohn and Colitis Knowledge score for patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Comoretto, R.(1);Azzolina, D.(2);Monaco, E.(3);Martinato, M.(3)*;
(1)University of Torino, Department of Public Health and Pediatrics, Torino, Italy;(2)University of Ferrara, Department of Environmental and Preventive Science, Ferrara, Italy;(3)University of Padova, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, Padova, Italy;
N02: Our life is a roller-coaster! A qualitative phenomenological study exploring the impact of IBD on family membersECCO’23 CopenhagenYear: 2023
Authors: Thapwong, P.(1)*;Norton , C.(1);Rowland, E.(2);Czuber-dochan, W.(1);
(1)King's College London-Florence Nightingale Faculty of Nursing & Midwifery, Department of Adult Nursing, London, United Kingdom;(2)King's College London- Florence Nightingale Faculty of Nursing & Midwifery, Department of Child and Family Health, London, United Kingdom;
N04: How to manage the concerns of patients with inflammatory bowel disease due to the transition from in-hospital to home management with oral or subcutaneous therapies: results of a survey of a cohort of patients in intravenous biologic treatment.ECCO’23 CopenhagenYear: 2023
Authors: Napolitano, D.(1)*;Settanni, C.R.(1);Parisio, L.(1);Schiavoni, E.(1);Pugliese, D.(1);Scaldaferri, F.(2);Gasbarrini, A.(2);Papa, A.(2);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, CEMAD Digestive Disease Center, Rome, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore- Roma- Italy, CEMAD Digestive Disease Center, Rome, Italy;
N05: Highlighting the critical contributions of Inflammatory Bowel Disease nurses in Canada: Perspectives from nurses, gastroenterologists, individuals living with IBD, and caregivers.ECCO’23 CopenhagenYear: 2023
Authors: Rohatinsky, N.(1);Zelinsky, S.(2)*;Chauhan, U.(3);Currie, B.(4);Frost, K.(5);Kroeker, K.(6);Ma, C.(7);Murray, K.(8);
(1)University of Saskatchewan, Health Sciences, Saskatoon, Canada;(2)University of Calgary, Community Health Sciences, Calgary, Canada;(3)McMaster University, Gastroenterology, Hamilton, Canada;(4)Nova Scotia Collaborative IBD Program, Gastroenterology, Halifax, Canada;(5)University of Toronto- Sick Kids Hospital, Pediatric Gastroenterology, Toronto, Canada;(6)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;(7)University of Calgary, Gastroenterology, Calgary, Canada;(8)The Canadian Digestive Health Foundation, Director- Research Patient Programs, Oakville, Canada;
N06: The Introduction of Nurse Led Preconception and Pregnancy Education Clinics for patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Gleeson, S.(1)*;Buckley, P.M.(2);McCarthy , D.J.(2);Moran, D.C.(2);O'Sullivan, C.(2);O'Sullivan, G.(2);O'Grady, D.J.(3);Sugrue, K.(2);
(1)Advanced Nurse Practitioner in Inflammatory Bowel Disease, IBD Centre- Mercy University Hospital, Cork, Ireland;(2)Mercy University Hospital, IBD Centre, Cork, Ireland;(3)Cork University Hospital, Gastroenterology, Cork, Ireland;
N07: A qualitative study on how patients with Inflammatory Bowel Disease feel supported in managing their disease using an appECCO’23 CopenhagenYear: 2023
Authors: Fallesen, J.P.(1)*;Minet, L.R.(2);Skjøth, M.M.(3);knudsen, T.(4);Kjeldsen, J.(5);
(1)Odense University Hospital- Department of Medical Gastroenterology S- University College Lillebaelt- Department of Nursing Odense-, University of Southern Denmark- Faculty of Health Sciences- Department of Clinical Research-, Odense, Denmark;(2)Odense University Hospital- Department of Geriatrics- University of Southern Denmark-, Department of Clinical research, Odense, Denmark;(3)Odense University Hospital, Department of Dermatology and Allergy Centre I, Odense, Denmark;(4)Hospital of South West Jutland Esbjerg- Department of Medical Gastroenterology-, Department of regional health research University of Southern Denmark, Esbjerg, Denmark;(5)Odense University Hospital, Department of Medical Gastroenterology- S. Research Unit of Medical Gastroenterology, Odense, Denmark;
N08: The emerging role of the IBD Care Manager: preliminary results from a survey by Italian IBD nursesECCO’23 CopenhagenYear: 2023
Authors: Napolitano, D.(1)*;Schiavoni, E.(1);Laterza, L.(1);Mora, V.(1);Sofo, L.(2);Pugliese, D.(1);Gasbarrini, A.(1);Scaldaferri, F.(1);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, CEMAD Digestive Disease Center, Rome, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, Department of Surgical Sciences, Rome, Italy;
N09: Exploration of medication adherence interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis: A Scoping Review of Randomised Controlled Trials.ECCO’23 CopenhagenYear: 2023
Authors: King, K.(1)*;McGuinness, S.(1);Watson, N.(1);Norton, C.(1);Chalder, T.(2);Czuber-Dochan, W.(1);
(1)King's College London, Faculty of Nursing- Midwifery & Palliative Care, London, United Kingdom;(2)King's College London, Institute of Psychiatry- Psychology and Neuroscience, London, United Kingdom;Bowel Research in Nursing Group
